Budapest, Hungary, May 31, 2011 / B3C newswire / - The majority share of Ubichem Research Ltd, a leading provider of chemistry services to the drug development sector, through Ubichem Pharma Services, has been acquired by financial investment company Lochlomond Holding Limited, owned by Marton Szoke, and is now independent of Ubichem Plc in the UK. The remaining minority share of Ubichem Research remains in the ownership of Mr. József Répási, Managing Director of Ubichem Research Ltd.
József Répási commented:
"It is a very exciting time for Ubichem Pharma Services. We have come a long way since Ubichem Research was founded in 1996, and this step will facilitate ambitious plans for further growth of our business, and enable us to provide an even better service to our customers."
Ubichem Pharma Services will continue to support the drug development programs of its pharma and biotech clients worldwide, from discovery through the clinic. Expertise in heterocyclic chemistry has enabled a catalogue of functionalised building blocks for use in medicinal chemistry projects to grow significantly over the last year. An experienced team of chemists offer custom synthesis and lead optimisation services, backed up by good in-house analytical capabilities. A strong focus on process R&D enables smooth scale-up in manufacturing APIs and intermediates. Recent regulatory approval for the supply of cGMP radiolabelled Active Pharmaceutical Ingredients (APIs) built on the approval obtained previously for the commercial supply of cGMP APIs.
About Ubichem Pharma Services
Ubichem Research was created in 1996 in Budapest, Hungary, and through Ubichem Pharma Services provides a comprehensive range of chemistry services (on lab to pilot plant scale) to support pharmaceutical development. These include cGMP API and intermediate manufacture, process research and development, analytical method development and validation, and radiolabelling.
József Répási, Ubichem Research Ltd.
Illatos Street 33, Budapest, H-1097 Hungary